Investigating how common primary aldosteronism is in patients with atrial fibrillation
Prevalence of Primary Aldosteronism in Patients With Atrial Fibrillation (ERETRIA Trial)
This study is trying to see how many people with atrial fibrillation also have primary aldosteronism.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 120 (estimated) |
| Ages | 18 Years to 100 Years |
| Sex | All |
| Sponsor | Aristotle University Of Thessaloniki Academic / other |
| Locations | 1 site (Thessaloniki) |
| Trial ID | NCT05973604 on ClinicalTrials.gov |
What this trial studies
This observational study aims to determine the prevalence of primary aldosteronism among patients diagnosed with atrial fibrillation. It will involve screening and confirmatory diagnostic tests to identify cases of primary aldosteronism in individuals with atrial fibrillation. The study will include patients with a confirmed diagnosis of atrial fibrillation, ensuring a thorough assessment of the condition's association with primary aldosteronism. The findings could provide insights into the relationship between these two conditions.
Who should consider this trial
Good fit: Ideal candidates for this study are individuals with a confirmed diagnosis of atrial fibrillation.
Not a fit: Patients who have already been diagnosed with primary aldosteronism or those with certain acute conditions may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to better identification and management of primary aldosteronism in patients with atrial fibrillation, potentially improving patient outcomes.
How similar studies have performed: While the specific prevalence of primary aldosteronism in atrial fibrillation has not been extensively studied, similar observational studies have successfully identified associations between various conditions.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Established diagnosis of atrial fibrillation with a standard surface ECG tracing of at least 30 seconds (either paroxysmal or persistent or permanent). Exclusion Criteria: * Diagnosis of primary aldosteronism * Diagnosis of heart failure, treated with mineralocorticoid receptor antagonists * Inability to be subjected to any confirmatory tests for primary aldosteronism * Acute vascular event (acute coronary syndrome, stroke, acute peripheral vascular event) within last 6 months * Renal replacement therapy * Incompetence of unwillingness to provide written informed consent
Where this trial is running
Thessaloniki
- Ippokratio General Hospital — Thessaloniki, Greece (Recruiting)
Study contacts
- Principal investigator: Maria Toumpourleka, MSc — Third Cardiology Department, Aristotle University of Thessaloniki, Thessaloniki, Greece
- Study coordinator: Maria Toumpourleka, MSc
- Email: m.toumpourleka@gmail.com
- Phone: 00302310892343
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.